KAUST's Laboratory of Stem Cells and Diseases, led by Assistant Professor Antonio Adamo, uses induced pluripotent stem cells (iPSCs) to model diseases like diabetes. The lab employs a reprogramming technique to revert patient fibroblasts into iPSCs, enabling the study of disease progression in vitro. Adamo's research focuses on enzymes and disregulated transcriptional/epigenetic mechanisms to understand disease onset. Why it matters: This research contributes to regenerative medicine and offers insights into metabolic diseases relevant to the GCC region.
Juan Carlos Izpisua Belmonte from the Salk Institute discussed aging and regenerative medicine at the KAUST 2019 Winter Enrichment Program. His team is combining gene editing and stem cell technologies to grow rat organs in mice and human cells in pig and cattle embryos. The Salk team is collaborating with KAUST to rejuvenate organs using noncoding RNAs and small metabolites. Why it matters: This research collaboration between KAUST and the Salk Institute explores innovative approaches to address age-related diseases and organ regeneration, with potential long-term impacts on healthcare in the region.
Khaled Alsayegh at the King Abdullah International Medical Research Center is creating a Saudi Stem Cell Donor Registry, with 80,000 potential donors identified. The aim is to identify universal donors, reprogram their cells into induced pluripotent stem (iPS) cells, and create a gene bank for matched tissue transplants. Alsayegh is collaborating with Jesper Tegnér at KAUST to create pacemaker cells using single-cell RNA sequencing. Why it matters: This initiative could revolutionize precision medicine in KSA by providing readily available, matched cells for transplants, reducing the need for patient-specific reprogramming and improving treatment outcomes.
Researchers at KAUST and Peking University Third Hospital have created a novel blastoid model for studying early human development using extended pluripotent stem cells (EPSCs). The blastoid is a 3D cell model mimicking the blastocyst phase, avoiding ethical concerns associated with using human embryos. The team showed that blastoids can be cultured to mimic post-implantation development, offering insights into early cell lineages. Why it matters: This innovation provides a way to study human embryogenesis without the ethical constraints of using actual embryos, potentially advancing our understanding of miscarriage and birth defects.
Dr. Laurent A. Lantieri delivered a keynote address at KAUST on April 17, 2017, discussing microsurgical procedures. The address included a brief history of microsurgery. The event took place in the University Auditorium. Why it matters: Such events expose the KAUST community to advances in specialized medical fields and potential research applications.
Researchers at the Rosalind Franklin Institute are using generative AI, including GANs, to augment limited biological datasets, specifically mirtron data from mirtronDB. The synthetic data created mimics real-world samples, facilitating more comprehensive training of machine learning models, leading to improved mirtron identification tools. They also plan to apply Large Language Models (LLMs) to predict unknown patterns in sequence and structure biology problems. Why it matters: This research explores AI techniques to tackle data scarcity in biological research, potentially accelerating discoveries in noncoding RNA and transposable elements.
John Pagano, CEO of The Red Sea Development Company and AMAALA, spoke at WEP 2022 about regenerative tourism. He highlighted that AMAALA and The Red Sea Project are the world's most ambitious regenerative projects today, using innovative sustainable methods. In partnership with KAUST, they undertook marine spatial planning simulations to protect the marine environment, conserve 75% of the islands, and designate nine conservation zones. Why it matters: This initiative signals a commitment to sustainable tourism development in Saudi Arabia, leveraging research and technology to minimize environmental impact while creating new industries.
KAUST researchers, in collaboration with the Salk Institute and Altos Labs, have identified a class of RNA (LINE-1) that, when compromised, leads to accelerated aging, as seen in progeria. They devised an antisense RNA strategy to block the aberrant function of L1 RNA, reversing the disease in mice and patient-derived cells. Published in Science Translational Medicine, the research suggests that targeting LINE-1 RNA could treat progeroid syndromes and other age-related diseases. Why it matters: This RNA-based approach provides a potential therapeutic avenue for treating premature aging diseases and extending human health span in the region and globally.